Barriers to achieving sustainability in pharmaceutical supply chains in the post-COVID-19 era

Liza, SA; Chowdhury, NR; Paul, SK; Morshed, M; Morshed, SM; Bhuiyan, MAT; Rahim, MA

Barriers to achieving sustainability in pharmaceutical supply chains in the post-COVID-19 era

Liza, SA Chowdhury, NR Paul, SK Morshed, M Morshed, SM Bhuiyan, MAT Rahim, MA

Permalink

Publisher:: Emerald
Publication Type:: Journal Article
Citation:: International Journal of Emerging Markets, 2023, 18, (12), pp. 6037-6060
Issue Date:: 2023-12

Closed Access

	Filename	Description	Size
	10-1108_IJOEM-11-2021-1680.pdf	Published version	439.46 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Liza, SA
dc.contributor.author	Chowdhury, NR
dc.contributor.author	Paul, SK
dc.contributor.author	Morshed, M
dc.contributor.author	Morshed, SM
dc.contributor.author	Bhuiyan, MAT
dc.contributor.author	Rahim, MA
dc.date.accessioned	2024-01-30T03:41:18Z
dc.date.available	2024-01-30T03:41:18Z
dc.date.issued	2023-12
dc.identifier.citation	International Journal of Emerging Markets, 2023, 18, (12), pp. 6037-6060
dc.identifier.issn	1746-8809
dc.identifier.issn	1746-8817
dc.identifier.uri	http://hdl.handle.net/10453/175060
dc.description.abstract	Purpose The recent pandemic caused by coronavirus disease 2019 (COVID-19) has significantly impacted the operational performances of pharmaceutical supply chains (SCs), especially in emerging economies that are critically vulnerable due to their inadequate resources. Finding the possible barriers that continue to impede the sustainable performance of SCs in the post-COVID-19 era has become essential. This study aims to investigate and analyze the barriers to achieving sustainability in the pharmaceutical SC of an emerging economy in a bid to help decision-makers recognize the most influential barriers. Design/methodology/approach To achieve the goals, two decision-making tools are integrated to analyze the most critical barriers: interpretive structural modeling (ISM) and the matrix of cross-impact multiplications applied to classification (MICMAC). In contrast to other multi-criteria decision-making (MCDM) approaches, ISM develops a hierarchical decision tool for decision-makers and cluster analysis of the barriers using the MICMAC method based on their driving and dependency powers. Findings The findings reveal that the major barriers are in a four-level hierarchical relationship where “Insufficient SC strategic plans to ensure agility during crisis” acts as the most critical barrier, followed by “Poor information structure among SC contributors,” and “Inadequate risk management policy under pandemic.” Finally, the MICMAC analysis validates the findings from the ISM approach. Originality/value This study provides meaningful insights into barriers to achieving sustainability in pharmaceutical SCs in the post-COVID-19 era. The study can help pharmaceutical SC practitioners to better understand what can go wrong in post-COVID-19, and develop actionable strategies to ensure sustainability and resilience in practitioners' SCs.
dc.language	English
dc.publisher	Emerald
dc.relation.ispartof	International Journal of Emerging Markets
dc.relation.isbasedon	10.1108/IJOEM-11-2021-1680
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1402 Applied Economics, 1503 Business and Management, 1505 Marketing
dc.subject.classification	3502 Banking, finance and investment
dc.subject.classification	3506 Marketing
dc.subject.classification	3507 Strategy, management and organisational behaviour
dc.title	Barriers to achieving sustainability in pharmaceutical supply chains in the post-COVID-19 era
dc.type	Journal Article
utslib.citation.volume	18
utslib.for	1402 Applied Economics
utslib.for	1503 Business and Management
utslib.for	1505 Marketing
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Business
pubs.organisational-group	University of Technology Sydney/Faculty of Business/Management Discipline
pubs.organisational-group	University of Technology Sydney/Strength - CAMGIS - Centre for Advanced Modelling and Geospatial lnformation Systems
utslib.copyright.status	closed_access	*
pubs.consider-herdc	true
dc.date.updated	2024-01-30T03:41:17Z
pubs.issue	12
pubs.publication-status	Published
pubs.volume	18
utslib.citation.issue	12

Abstract:

Purpose The recent pandemic caused by coronavirus disease 2019 (COVID-19) has significantly impacted the operational performances of pharmaceutical supply chains (SCs), especially in emerging economies that are critically vulnerable due to their inadequate resources. Finding the possible barriers that continue to impede the sustainable performance of SCs in the post-COVID-19 era has become essential. This study aims to investigate and analyze the barriers to achieving sustainability in the pharmaceutical SC of an emerging economy in a bid to help decision-makers recognize the most influential barriers. Design/methodology/approach To achieve the goals, two decision-making tools are integrated to analyze the most critical barriers: interpretive structural modeling (ISM) and the matrix of cross-impact multiplications applied to classification (MICMAC). In contrast to other multi-criteria decision-making (MCDM) approaches, ISM develops a hierarchical decision tool for decision-makers and cluster analysis of the barriers using the MICMAC method based on their driving and dependency powers. Findings The findings reveal that the major barriers are in a four-level hierarchical relationship where “Insufficient SC strategic plans to ensure agility during crisis” acts as the most critical barrier, followed by “Poor information structure among SC contributors,” and “Inadequate risk management policy under pandemic.” Finally, the MICMAC analysis validates the findings from the ISM approach. Originality/value This study provides meaningful insights into barriers to achieving sustainability in pharmaceutical SCs in the post-COVID-19 era. The study can help pharmaceutical SC practitioners to better understand what can go wrong in post-COVID-19, and develop actionable strategies to ensure sustainability and resilience in practitioners' SCs.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/175060